



Published in final edited form as:

Stem Cell Res. 2015 May ; 14(3): 307–322. doi:10.1016/j.scr.2015.02.001.

High-level *Gpr56* expression is dispensable for the maintenance and function of hematopoietic stem and progenitor cells in mice

Tata Nageswara Rao^{1,2}, Jonathan Marks-Bluth³, Jessica Sullivan^{1,2}, Manoj K. Gupta², Vashe Chandrakanthan³, Simon R. Fitch⁴, Katrin Ottersbach⁴, Young C. Jang^{1,2}, Xianhua Piao⁵, Rohit N. Kulkarni², Thomas Serwold², John E. Pimanda³, and Amy J. Wagers^{1,2,*}

¹Howard Hughes Medical Institute, and Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA

²Joslin Diabetes Center and Harvard Medical School, Boston, MA, 02215, USA

³Lowy Cancer Research Centre and the Prince of Wales Clinical School, University of New South Wales, Sydney, NSW 2052, Australia

⁴Department of Haematology, Cambridge Institute for Medical Research and Wellcome Trust – Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge CB2 0XY United Kingdom

⁵Division of Newborn Medicine, Boston Children's Hospital, Harvard Medical School, MA, USA

Abstract

Blood formation by hematopoietic stem cells (HSC) is regulated by a still incompletely defined network of general and HSC-specific regulators. In this study, we analyzed the role of G-protein coupled receptor 56 (*Gpr56*) as a candidate HSC regulator based on its differential expression in quiescent relative to proliferating HSCs and its common targeting by core HSC regulators. Detailed expression analysis revealed that *Gpr56* is abundantly expressed by HSPCs during definitive hematopoiesis in the embryo and in the adult bone marrow, but its levels are reduced substantially as HSPCs differentiate. However, despite enriched expression in HSPCs, *Gpr56*-deficiency did not impair HSPC maintenance or function during steady-state or myeloablative stress-induced hematopoiesis. *Gpr56*-deficient HSCs also responded normally to physiological and pharmacological mobilization signals, despite the reported role of this GPCR as a regulator of cell adhesion and migration in neuronal cells. Moreover, *Gpr56*-deficient bone marrow engrafted with equivalent efficiency as wild-type HSCs in primary recipients; however, their reconstituting ability was reduced when subjected to serial transplantation. These data indicate that although

© 2015 Published by Elsevier B.V.

*To whom correspondence should be addressed: Amy J. Wagers, PhD; Joslin Diabetes Center, One Joslin Place, Boston, MA 02215; amy_wagers@harvard.edu; Phone: +1-617-309-2590; Fax: +1-617-309-2593.

Disclosure of Potential Conflicts of Interest

The authors declare no financial conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

GPR56 is abundantly and selectively expressed by primitive HSPCs, its high level expression is largely dispensable for steady-state and regenerative hematopoiesis.

Keywords

Hematopoietic stem cells; GPR56; Heptad target; Self-renewal; hematopoietic transplant; G-protein coupled receptor

Introduction

Hematopoietic stem cells (HSCs) are the only adult stem cells that can sustain lifelong blood cell production through their self-renewal and differentiation capacity. During embryonic and adult hematopoiesis, HSC homeostasis is dynamically regulated by facultative actions of cell-intrinsic and extrinsic regulators (1, 2). Recent studies have identified several transcription factors as master regulators of HSC homeostasis, including *Runx1*, *Evi1*, *Gata2*, *Scl*, *Erg*, *Lyl1*, *Lmo2*, among others (2–4). In addition, HSC functional properties and transcriptional programs are modulated by extrinsic factors (including, cytokines, chemokines, growth factors, and extracellular matrix proteins), which act through HSC-expressed cell surface receptors (5–7). In adult bone marrow, HSCs reside in a specialized microenvironment, called the stem cell ‘niche’. HSCs continuously communicate with their niche, and depend on niche-derived signals to maintain their survival, self-renewal, retention, and differentiation capacity.

Over the last decade, several studies employing genome wide transcriptional profiling analysis have revealed a unique HSC transcriptional signature and suggested that genes specifically and highly expressed in HSCs may determine HSC functional properties (2, 8–12) and can even specify HSC fate from more mature hematopoietic cells (13). Although such studies have focused largely on transcriptional regulators of HSCs, it is clear that cell surface receptors can play an equally important role in the maintenance and regenerative function of stem cells by translating signals from extracellular ligands into cell physiological changes (14). G-protein coupled receptors (GPCRs) constitute one of the largest and most diverse families of membrane proteins and mediate many biological functions through ‘outside in’ signaling between the cell and its microenvironments (15). Yet, despite their functional significance in numerous cell types, few GPCRs have been investigated for their role in the regulation of HSCs. For this reason, we sought to identify the candidate HSC specific cell surface receptors by analysis of published gene expression data sets (2, 11). From these studies, G-protein coupled receptor 56 (*Gpr56*) emerged as a highly expressed HSC-specific cell surface receptor that was present at increased levels in quiescent relative to proliferating HSCs and targeted by core HSC regulators.

GPR56 is a member of the adhesion type GPCR family (16), and has been implicated in regulating cell proliferation, survival, adhesion, and migration of various cell types (17, 18), although its physiological role in hematopoiesis is largely unexplored. In humans, mutations of *GPR56* have been linked to defects in the organization of the cerebral cortex in the brain, leading to a disorder known as bilateral frontoparietal polymicrogyria (BFPP) (19). Due to its abnormal expression levels in various cancers, GPR56 is also predicted as a tumor

suppressor (20). This functional versatility in various cells types, and the predominant expression pattern of GPR56 in quiescent HSCs, led us to hypothesize that this adhesion type receptor might play a critical role in regulating HSCs.

In this study, we analyzed HSC development and hematopoietic function in gene-modified mice deficient for *Gpr56*. These studies revealed that high level expression of *Gpr56* is largely dispensable for the development, maintenance, and differentiation of adult hematopoietic stem and progenitor cells (HSPCs) during both steady-state and myeloablative stress-induced hematopoiesis. These data suggest that low levels of GPR56 or compensatory functions of related GPCRs are sufficient to support most hematopoietic functions and raise questions regarding previously reported defects in the maintenance and function of adult hematopoietic stem and progenitor cells in *Gpr56*-deficient mice (21).

Materials and Methods

Mice

Gpr56-deficient mice (B6N.129S5-*Gpr56*^{tm1Lex}/Mmcd) were generated by Genentech (South San Francisco, CA, USA), and have been reported previously (22–24). Genomic modification of *Gpr56* alleles was verified by genotyping PCR using tail tip DNA. The following primers were used with an annealing temperature of 58°C to identify the WT (639bp) and *Gpr56*-deficient (369bp) alleles: DNA085-5 5'-CGAGAAGACTTCCGCTTCTG-3'; DNA085-14 5'-AAAGTAGCTAAGATGCTCTCC-3'; Neo3a 5'-GCAGCGCATCGCCTTCTATC-3'. Wild-type littermates from heterozygous breeders were used as controls. While prior studies reported an absence of functional GPR56 protein in homozygous *Gpr56*-deficient mice (21–24), our analysis by western blot and flow cytometry suggests residual protein expression in multiple cellular compartments, including the brain, liver and hematopoietic system (see Fig. 2B and S2B–E). B6.SJLPtrca Pep3b/BoyJ (CD45.1) mice were purchased from The Jackson Laboratory (www.jax.org). All experiments involving mice were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Joslin Diabetes Center and Harvard University.

In situ hybridization

Digoxigenin-labeled RNA probes were hybridized using the Ventana Discovery platform (Tucson, AZ). Data can be accessed at <http://www.emouseatlas.org/>.

Flow Cytometry

Total bone marrow (BM), spleen, thymus and peripheral blood (PB) were harvested from age- and sex-matched mice, as indicated. BM cells were harvested from long bones (2 tibias and 2 femurs) by flushing with 25G needle using staining media (Dulbecco's PBS+ 5% FCS), resuspended, and filtered through a 70µm cell strainer. BM and splenocytes were subjected to red blood cell lysis (except when analyzing erythrocytes) using ACK lysis buffer (Lonza). To identify HSPCs, cells were stained with biotinylated lineage marker mix (Lin: Anti-CD3e (17-A2), Anti-CD4 (L3T4), anti-CD8 (53–6.72), anti-B220 (RA3-6B2), anti-TER-119, anti-Gr-1 (RB6-8C5), anti-Mac-1 (M1/70), followed by Streptavidin PE-Texas Red. Cells were further stained with APC-anti-c-Kit (2B8), PE-anti-CD150

(TC15-12F12.2), Biolegend), PECy7-anti-Sca-1 (E13-161.7), FITC-anti-CD34 (RAM34), FITC-anti-CD48 (HM48-1) (eBiosciences); PE-anti-Flt3 (A2F10.1), PE-Fc γ RII/III (2.4G2) (BD). BM myeloid progenitor subsets were identified as follows: common myeloid progenitors (CMP, Lin⁻Sca1⁻cKit⁺CD34⁺Fc γ RII/III^{med}), granulocyte monocyte progenitors (GMPs, Lin⁻Sca1⁻cKit⁺CD34⁺Fc γ RII/III⁺), and megakaryocyte erythrocyte progenitors (MEPs, Lin⁻Sca1⁻cKit⁺CD34⁻Fc γ RII/III^{low}). Common lymphoid progenitors (CLPs; Lin⁻CD127⁺Flt3⁺) were identified using Lin mix, PECy7-anti-CD127 (A7R34) (eBiosciences), and PE-anti-Flt3 (A2F10.1) antibodies. BM and splenic erythrocyte progenitors, BM megakaryocyte progenitors, and B-cell progenitor subsets were identified as previously described (25). For analysis of immature thymic subsets, Lin mix, APC-anti-c-Kit (2B8), PECy7-anti-CD25 (M-A251) (BD) were used. Thymocyte differentiation was studied using CD4 and CD8 staining. Mature B cells, T cells, and myeloid cells were identified using B220⁺, CD3⁺, and CD11b⁺ Gr1⁺ staining, respectively. Cell surface GPR56 expression on BM HSPCs was assessed by using anti-human GPR56 antibody (clone: CG4, Biolegend). Sytox-Blue (Invitrogen) was used to exclude dead cells during FACS analysis. Stained cells were analyzed on LSRII flow cytometer, and cell sorting was done on a FACS Aria II (BD). Data were analyzed by using FACS Diva software (BD) or FlowJo software (Tree Star). HSPCs from the AGM were identified by staining with CD41-Brilliant Violet 421 (Biolegend; clone MWReg30), CD34-FITC (BD Bioscience; clone RAM34), CD45-PE (eBiosciences; clone 30-F11), and cKit-APC (eBiosciences; clone 2B8). AGM sorts were performed on an Influx cytometer.

Peripheral Blood (PB) analysis and differential count

PB was collected from the tail vein of adult mice into EDTA-coated tubes (BD), and differential blood counts were determined using a Hemavet 950 (Drew Scientific).

RT-PCR

For analysis of Col3A and *Gpr56* expression in the AGM, tissues were dissociated and RNA isolated, reverse transcribed and amplified according to the methods described in (26), using the following primer sets: MmGpr56, JP593F 5'-ATCAGCCAGCAGTTACAG-3' and JP593R 5'-GAAGCAACAGCGAGTATG-3'; MmCol3a, JP596F 5'-GAATCTGTGAATCATGTCCAACACTG-3' and JP596R 5'-CCACCCATTCTCCCACTC-3'; SDHA_F 5'-TTG CTA CTG GGG GCT ACG GGC-3' and SDHA_R 5'-TGA CCA TGG CTG TGC CGT CC-3'; B-actin_F 5'-TCC TGG CCT CAC TGT CCA-3' and B-actin_R 5'-GTC CGC CTA GAA GCA CTT GC-3'. For analysis of *Gpr56* expression in adult cell populations, total RNA was extracted from the indicated FACS-purified cells by RNeasy Micro Kit following manufacturer's instructions (Qiagen) and reverse transcribed into cDNA using SuperScript Vilo cDNA Synthesis kit (Invitrogen). Quantitative PCR was performed with an AV7900 PCR system using Taqman Gene Expression master mix kit (Applied Biosystems). Taqman gene expression primer sets were used to quantify the *Gpr56* (Mm00817704_m1) and β -actin (Mm00607939_s1) gene expression levels. Expression levels of the β -actin house-keeping gene were used to normalize *Gpr56* expression in indicated subsets.

Western blot analysis

Total protein lysates from the FACS-sorted BM HSPCs, liver and embryonic brain (embryonic day (E) 14.5) were subjected to standard western blot analysis. Total protein was loaded onto 4–16% gradient SDS-PAGE gel and transferred onto a PVDF membrane. Mouse anti-human GPR56 monoclonal antibody (1:500 dilution, Millipore catalog #MABN310, (27)) was used to detect GPR56 protein. β -actin (Santa Cruz) used as loading control.

Colony-forming unit cell assay (CFU-C)

BM and PB cells were mixed with 300 μ l of IMDM and 4ml of defined semisolid methylcellulose medium (Methocult GF3434 medium, StemCellTechnologies). Cells were then cultured in triplicate in 6-well plate with 1.1ml/plate at a density of 1×10^4 cells for BM and 1×10^5 cells for PB. The total number of colonies was counted at day 10 under an inverted microscope.

Cell cycle analysis and apoptosis assay

BM and thymocyte cell cycle status was determined using Ki67/Hoechst staining. Cells were first stained with surface antibodies to identify indicated subsets and then fixed in Cytotfix buffer for 20min, washed and permeabilized using Cytotfix/perm buffer (BD) before staining with Ki67-FITC (B56) antibody (BD) for 30min at 4°C. Cells were washed once with permeabilization buffer after staining and incubated with Hoechst dye (20 μ g/ml) and analyzed by BD LSR II flow cytometer. To assess the *in vivo* cell proliferation rate of thymocytes, 1mg of BrdU was injected (i.p.) and mice were sacrificed 5h later (short-term pulse). BrdU incorporation was detected with the BrdU Flow Kit following the manufacturer's instructions (BD Biosciences). To assess survival rate, mononuclear cells (1×10^6) from BM or thymus were surface stained with the appropriate antibodies to identify indicated subsets. Cells were washed with PBS and then resuspended in 100 μ l of Annexin V binding buffer (BD) and incubated with AnnexinV and 7-AAD (BD Pharmingen) for 15 min. at room temperature. Cells were resuspended in additional 400 μ l of Annexin V binding buffer and analyzed immediately using a BD LSR II flow cytometer.

Bone marrow (BM) reconstitution assays

For competitive repopulation experiments, total BM cells (1×10^6) from either WT control littermates or *Gpr56*-deficient mice (CD45.2) were mixed with equal number (1:1) of recipient type cells (CD45.1) and transplanted into lethally irradiated (950rads) B6SJL Ptpca Pep3b/BoyJ (CD45.1) congenic recipients by lateral tail vein injections (in 200 μ l PBS/mouse). At the indicated time points post-transplantation, recipient mouse PB was collected, erythrocytes were depleted with ACK buffer (LONZA), and the remaining leukocytes were stained with anti-mouse CD45.2, CD45.1, CD3, B220, Gr-1, and CD11b antibodies. Stained cells were analyzed by FACS LSRII (BD).

5-FU treatment

5-Fluorouracil (5-FU, Sigma) was administered to mice intravenously at a dose of 150mg/kg. Hematopoietic recovery was monitored by differential blood cell counts using

the Hemavet 950 (Drew Scientific), at indicated time points. For survival assay, 5-FU was administered intraperitoneally at a dose of 150mg/kg weekly for a total of 3 weeks and the survival of individual mice was monitored daily.

***In vitro* Transwell migration assay**

In vitro migration of HSPCs was performed using Transwells (6.5mm diameter inserts; 5µm pore size; Corning). FACS-purified HSPCs were loaded onto Transwell inserts (10⁵ cells/well in 100µl of medium). The lower chambers contained 600µl of RPMI medium supplemented with 10% FCS and with SDF-1 (100ng/ml) or without SDF-1 (R&D systems). Cells were incubated for 4 hours at 37°C and 5% CO₂. Migrating cells from the lower chambers were collected and counted by FACS with normalization using Countbright Absolute counting beads (Invitrogen). The percentage of migrated cells was calculated by dividing the absolute number of migrated cells by the input cell number.

***In vivo* lodging assay**

For *in vivo* lodging assays, FACS-isolated Lin⁻Kit⁺ cells from WT and KO mice were labeled with 4µM of PKH67 (Sigma) vital fluorescent dye and intravenously infused into the non-irradiated wild-type littermates. Sixteen hours post-transplantation, BM and spleen were harvested from the recipient mice and analyzed for the labeled lodged cells by FACS using FITC channel.

G-CSF treatment and Mobilization assay

Cytokine induced mobilization of HSPCs was performed by daily subcutaneous administration of G-CSF (Filgrastim, Amgen), 300µg/Kg in 200µl of PBS for five consecutive days, as previously described (9, 28). Control mice received PBS only. PB and spleen was collected on the sixth day and analyzed for HSPC (LSK) frequency by FACS.

Statistics

Statistical significance was determined with Student's *t*-test using GraphPad Prism Software Version 6.0. For the Kaplan-Meier analysis of survival curves, a log-rank nonparametric test (Mantel-Cox) was performed. *p*-values are denoted with *(*p*<0.05); **(*p*<0.01); and *n.s.* (not significant).

Results

***Gpr56* is abundantly expressed in HSCs during definitive hematopoiesis in the mouse embryo and is a heptad target**

Recent studies have postulated that genes specifically expressed in HSCs relative to their more differentiated progeny may play an important role in fine-tuning HSC properties (9, 29). To identify candidate HSC-specific regulators we made use of published data sets that identified genes uniquely expressed by quiescent, versus proliferating, HSCs (Q-group, (11)) in combination with a proximal promoter-based analysis of genes that are bound by seven key hematopoietic transcription factors (*Scl*, *Gata2*, *Runx1*, *Erg*, *Fli1*, *Lyl1*, and *Lmo2*) (2), which together are referred to as Heptad targets (Fig. 1A). Comparative analysis of these

gene sets identified a total of 81 transcripts that showed enriched expression in quiescent HSCs and contained Heptad binding sites in their upstream regions.

Although much attention has been focused on transcriptional regulators of HSCs, it is clear that surface receptors play an equally important role. Based on the rationale that cell quiescence is likely to be mediated by niche interactions (5), we further filtered this gene list for cell surface receptors, identifying eight receptors (*Gpr56*, *Adrb2*, *Ifnar2*, *Vldlr*, *Fgfr1*, *Igf1r*, *Il1r1* and *Csf2rb* (*Il3rBC*)) (Supplemental Table 1) specifically enriched in quiescent HSCs and containing Heptad binding sites in their proximal regions. Of these eight, we focused on *Gpr56* for further investigation because of its unknown physiological function, the availability of *Gpr56*-deficient mice, and because prior studies implicated this receptor in the regulation of adhesion and migration of neuronal progenitors and malignant cells (22–24). Interestingly, a study published during the preparation of this manuscript reported a disruption of HSC localization, cycling and *in vivo* repopulating capacity in mice deficient for *Gpr56* expression (21).

To determine the role of *Gpr56* during the early stages of hematopoietic development, we examined its expression during definitive hematopoiesis in the aorta-gonad-mesonephros region (AGM) and fetal liver (FL) of mouse embryos. In situ hybridization revealed expression of *Gpr56* transcripts in emerging clusters of blood cells and adjacent endothelium in E11 AGM and in E11 FL cells in the mouse embryo (Fig. 1B). Notably, quantitative RT-PCR analysis revealed that collagen III (*Col3a*) the reported ligand of GPR56 (18) is expressed in E11 AGM mesenchymal cells (MC; CD34⁻CD45⁻cKit⁻), but not in endothelial cells (EC; CD34⁺CD45⁻), or in AGM or FL HSCs (CD34⁺CD45⁺c-kit⁺CD41^{int}) (Fig. 1C). Conversely, *Gpr56* was absent in E11 AGM mesenchymal cells and endothelial cells, but was significantly elevated in HSCs during the developmental transition from E11 AGM to E14 fetal liver stages (Fig. 1C), suggesting a possible role for GPR56 signaling in the regulation of HSCs during early definitive hematopoiesis. Consistent with this, a recent study in zebrafish embryos reported a defect in HSC emergence in the caudal hematopoietic tissue upon *gpr56* knockdown by morpholino oligos (30).

***Gpr56* is highly expressed in adult HSCs, but is dispensable for steady-state maintenance of adult stem and progenitor cells**

We next determined the expression pattern of *Gpr56* in adult bone marrow. Consistent with prior studies (11), quantitative RT-PCR analysis of purified HSPCs from adult wild type C57BL/6 bone marrow revealed that *Gpr56* is expressed most abundantly in primitive HSPCs, with the highest expression detected in long-term, self-renewing HSCs (LT-HSCs, LSKCD34⁻Flt3⁻) followed by short-term (ST-HSCs, LSKCD34⁺Flt3⁻) and multipotent progenitors (MPPs, LSKCD34⁺Flt3⁺) (Fig. 2A). Strikingly, *Gpr56* expression levels were progressively down-regulated in lineage-restricted lymphoid and myeloid progenitor subsets (Fig. 2A). We also analyzed *Gpr56* expression across a broad range of hematopoietic subsets, taking advantage of two publically accessible databases/webservers, ImmGen (<https://www.immgen.org/>) and HemaExplorer (<http://servers.binf.ku.dk/hemaexplorer>; (31)), in which microarray based mRNA expression profiles of previously reported FACS sorted populations of immature and mature hematopoietic subsets can be visualized.

Consistent with our qRT-PCR results, within these data sets, *Gpr56* expression was most abundant in the primitive HSC fraction, when compared to any other progenitor subset in the BM or mature hematopoietic cell subset in the periphery (Supplemental Fig. S1A, B). We also noted moderate expression of *Gpr56* in megakaryocyte progenitors (MkP) in the BM, and in early thymic progenitors (Supplemental Fig. S1B). Together, these results indicate that *Gpr56* expression is tightly regulated within primitive HSPCs, and that the level of *Gpr56* expression declines sharply as HSCs undergo lineage restriction and differentiation into mature blood lineages.

These results prompted us to explore further the role of GPR56 in adult hematopoiesis. We hypothesized that if enriched expression of *Gpr56* predicted its functional activity, then we could expect to see changes in HSPCs and in steady-state hematopoiesis in *Gpr56*-deficient mice (Supplemental Fig. S2A). We thus performed FACS-immunophenotyping to assess the frequencies of specific HSPC subsets in the BM of adult *Gpr56*-deficient mice. Interestingly, although prior studies of these animals have suggested that they lack GPR56 protein entirely (18, 21, 22, 24), our analysis using highly specific anti-GPR56 mAb (18) revealed some residual expression in the brain, liver, and hematopoietic compartment (Supplemental Fig. S2B–D). Nonetheless, flow cytometric analysis of HSPC populations in these animals indicated a substantial reduction of GPR56 protein on the cell surface, including a >4-fold reduction of GPR56 staining of LT-HSCs from *Gpr56*-deficient BM (Fig. 2B and Supplemental Fig. S2E).

Further analysis of hematopoietic subsets in *Gpr56*-deficient mice indicated that, despite the abundant and relatively restricted expression of this protein by primitive HSPCs, *Gpr56*-deficient mice displayed no abnormalities in steady-state hematopoiesis. Total BM cellularity and frequencies of LT-HSC (LSKCD34⁻CD135⁻), ST-HSC (LSKCD34⁺CD135⁻) and MPPs (LSKCD34⁺CD135⁺) in the BM were indistinguishable from WT control littermates (Fig. 2C–E). Likewise, further enrichment of HSCs within the LSK subset, using SLAM family receptors expression (LKSCD150⁺CD48⁻, (32)), also revealed HSC frequencies that were unaffected by the reduction of *Gpr56* (Fig. 2F). We did observe a mild reduction in LT-HSC (LSKCD34⁻CD135⁻) frequency in *Gpr56*-deficient BM, but this reduction was not statistically significant ($p=0.209$). A detailed analysis of lineage committed progenitors, including myeloid progenitors (MPs), common myeloid progenitors (CMPs), granulocyte monocyte progenitors (GMPs), and megakaryocyte erythrocyte progenitors (MEPs), and common lymphoid progenitors (CLPs) similarly showed frequencies indistinguishable from those in wild type BM (Fig. 2G–I and Supplemental Fig. S3A–B). B-cell progenitors were mildly decreased at the Pre-B and Pro-B stages; however, this defect resolved at the mature B cell stage (Supplemental Fig. S3C–D).

We also performed detailed immunophenotyping and differential blood counts of mature hematopoietic lineages in the BM and PB to determine if specific lineages might be affected in *Gpr56*-deficient mice. The frequencies of mature T-cells (CD3⁺), B-cells (B220⁺), myeloid cells (CD11b⁺Gr-1⁺), and erythroid lineage cells in the BM and the overall PB cell counts were unchanged, indicating unaffected lymphopoiesis and myelopoiesis in mice with reduced levels of functional GPR56 (Table 1 and Supplemental Fig. S3C, E–G). Altogether,

these results indicate that despite its enriched expression in primitive HSPCs, high level GPR56 is largely dispensable for steady-state HSPC maintenance and hematopoietic differentiation.

Enlarged thymuses and increased frequency of early thymic precursors in *Gpr56*-deficient mice

To further assess any effects on blood cell development in the absence of high levels of GPR56, we investigated hematopoiesis in the spleen and thymus of *Gpr56*-deficient mice. Analysis of splenic lineages revealed normal cellularity and frequencies of myeloid, B-cells and erythroid lineages (Supplemental Fig. S4A–C); however, the frequencies of CD4⁺ and CD8⁺ T cells were slightly but significantly reduced in *Gpr56*-deficient mice (Fig. S4D–E). We also consistently observed enlarged thymuses in *Gpr56*-deficient mice compared with age-matched littermate controls (Fig. 3A). Thymic analysis showed that *Gpr56*-deficient mice at 8–14 weeks of age exhibited significantly higher numbers of thymocytes (~1.4-fold) compared with age-matched controls (159±7 for WT and 225±13 for *Gpr56*-deficient mice, $p=0.0002$) (Fig. 3B). In addition, histological analysis revealed that the thymus of *Gpr56*-deficient mice possessed abnormal cortex and medullary proportions with an enlarged medullary region (Fig. 3C).

It has been reported that increased frequency of early thymic progenitors (ETP) due to increased recruitment of progenitors from the BM into the thymus could lead to increased thymic cellularity (33). Therefore, we next studied the early stages of thymocyte development to determine whether *Gpr56*-deficiency increased the ETP and CD4/CD8-double negative thymocyte subsets. Fractionation of Lin⁻ thymocytes using CD25 and c-Kit surface expression revealed that *Gpr56*-deficient mice have significantly higher percentages and absolute numbers of ETPs (Lin⁻CD25⁻c-Kit⁺) in the thymus (Fig. 3D–F). Analysis of subsequent developmental stages showed that *Gpr56*-deficient mice also possessed higher numbers of DN2 (Lin⁻CD25⁺c-Kit⁺), DN3 (Lin⁻CD25⁺c-Kit^{lo}) and mature CD4 and CD8 single positive cell subsets (Fig. 3D–G, and data not shown).

It is possible that increased cycling or survival of early thymic precursors could account for the increased cellularity in *Gpr56*-deficient mice. Thus, to determine cellular proliferation rates, we pulsed these mice with BrdU for 5h and analyzed the frequency of BrdU⁺ cells; however, WT and *Gpr56*-deficient ETPs and DN2 cells showed comparable proliferation rates (Fig. 3H). Cell survival measurements using Annexin V staining likewise showed that *Gpr56*-deficient ETPs exhibited similar rates of apoptosis as their WT counterparts (Fig. 3I). Analysis of all other developmental stages, including CD4⁺, CD8⁺, and DP stages, also showed comparable rates of cycling and comparable frequencies of apoptotic cells between WT and *Gpr56*-deficient thymocytes (data not shown). The observed increase in the number of ETPs and DN2 cells in *Gpr56*-deficient thymuses, despite normal proliferation and survival rates, suggests that *Gpr56* deficiency may alter the intrinsic ability of *Gpr56*-deficient BM progenitors to migrate from the BM into the thymus. It is also possible that *Gpr56*-deficient thymuses may be more receptive to BM progenitor entry. Regardless, increased numbers of ETPs and DN2 cells likely account for the increased number of subsequent thymocyte stages, and hence the overall increase in thymic cellularity.

High-level GPR56 expression is largely dispensable for regulation of HSPC proliferation and survival and for reconstitution of the hematopoietic system after BM transplantation

Although detailed immunophenotyping analysis by flow cytometry suggested no reduction in HSPC content in *Gpr56*-deficient BM (Fig. 2), it is possible that homeostatic effects during development could mask defects in HSPC maintenance in *Gpr56*-deficient mice through functional compensatory mechanisms. Therefore, we next tested whether changes in cell proliferation or survival might have provided a selection advantage toward normal HSPC pool size. To directly assess the cell-cycle status of *Gpr56*-deficient HSPCs, we stained the cells with Ki-67, a proliferation marker, and Hoechst 33342 for DNA content analysis. No differences were noted in the percentages of quiescent (G_0 , Ki67⁻Hoechst⁻) or cycling cells (S/G2/M, Ki67⁺Hoechst⁺) in WT and *Gpr56*-deficient HSPC subsets (Fig. 4A–B). Next, we co-stained cells with Annexin V and 7-AAD and analyzed possible effects on survival by flow cytometry. The percentages of early apoptotic cells (Annexin V⁺ 7-AAD⁻) among *Gpr56*-deficient LSK HSPCs cells were not significantly different from WT littermates (Fig. 4C, 6.88 ± 1.13 and 5.83 ± 0.8 , for *Gpr56*-deficient and WT, respectively) ($p=0.47$). These findings are in line with our earlier observations that phenotypic HSPCs are largely intact in *Gpr56*-deficient BM. Altogether, these results suggest that *Gpr56*-deficiency does not affect HSPC quiescence or survival in the adult mouse bone marrow during steady-state conditions.

To evaluate the hematopoietic reconstituting ability of *Gpr56*-deficient HSCs, we next performed competitive repopulation assays in which equal numbers of total BM cells (CD45.2⁺) from WT or *Gpr56*-deficient mice were mixed at a 1:1 ratio with congenic (CD45.1⁺) WT competitor cells and transplanted into lethally irradiated primary recipient mice (Fig. 4D). Previously, Saito et al. (2013), reported that *Gpr56*-deficient HSCs possess reduced reconstitution potential due in part to reduced homing capacity. We speculated that if GPR56 regulates HSC homing capacity we should see an alteration in hematopoietic repopulation in recipients particularly at early stages after BM transplantation; however, analysis of peripheral blood of recipient mice at 4-weeks after transplant showed no significant differences between WT and *Gpr56*-deficient donors in either the reconstitution of total hematopoietic lineages (percent CD45.2⁺) or the repopulation of B (B220⁺), T (CD3⁺) and myeloid cells (Gr1⁺CD11b⁺) (Fig. 4E–H), suggesting that high level GPR56 expression is not needed for HSC homing or short-term reconstitution in primary transplant recipients. Subsequent analysis of long-term reconstitution, at 8, 12, and 20w post-BMT, revealed that *Gpr56*-deficient donors did not differ in their ability to reconstitute B, T, and short-lived myeloid cells (a measure for intact HSC activity) in the PB or BM of primary recipients (Fig. 4E–I). Furthermore, the frequencies of donor LSK cells in the BM of primary recipient mice were also similar (80.9 ± 5.9 vs. 70.8 ± 22.5 , $p=0.41$) in the two groups (Fig. 4J).

To further assess the regenerative capacity of *Gpr56*-deficient HSCs, we performed secondary transplantation (which imposes extreme proliferative stress for HSCs) using total BM cells from primary recipients harvested 20 weeks after the primary transplant. Intriguingly, while donor B-cell and T-cell chimerism was almost identical in secondary recipients of WT and *Gpr56*-deficient marrow, donor myeloid lineage chimerism in the PB

($p=0.001$) and the total donor cell frequency in the BM was significantly reduced ($p=0.0027$) in secondary recipients of *Gpr56*-deficient BM (Fig. 4K–L). Analysis of the LSK compartment also showed significant reduction of HSPC frequency (86.3 ± 11.7 for WT vs 42.2 ± 24.6 for *Gpr56*-deficient mice, $p=0.006$) in secondary recipients of *Gpr56*-deficient BM (Fig. 4M). Taken together, these results indicate that although high levels of GPR56 appear dispensable for hematopoietic reconstitution in primary recipients, *Gpr56*-deficient HSCs can show reduced regenerative capacity when subjected to repeated proliferative stress induced by serial BM transplantation.

***Gpr56*-deficiency does not alter recovery from myelosuppression or impair the physiological or pharmacological mobilization of HSPCs**

The defects we observed upon serial transplant of *Gpr56*-deficient BM cells suggested that reduction of GPR56 protein levels on HSPCs might impact the hematopoietic function of these cells when subjected to repeated proliferative or migratory stress. During steady-state conditions, the majority of HSCs are maintained in a quiescent state (G0) in the BM; however, during infections, and in response to irradiation or chemotoxic drugs, HSCs exit quiescence and enter the cell cycle to replenish the hematopoietic system. These cells also can be induced by such stimuli to migrate from the BM niche to seed extramedullary hematopoiesis (34). During these responses, the balance between proliferation and differentiation must be tightly controlled to sustain the ability of HSCs to regenerate the hematopoietic system (35).

To elucidate whether GPR56 plays any role regenerating the hematopoietic system during such conditions, we treated mice with a single dose of 5-fluorouracil (5-FU) intravenously, a cytotoxic drug that kills actively cycling cells and induces quiescent HSCs to rapidly proliferate. We monitored the kinetics of hematopoietic recovery in the peripheral blood at every fourth day for a total of 24 days after 5-FU treatment. In agreement with previous studies, we observed multi-lineage hematopoietic recovery, including white blood cells (WBC), platelets, and red blood cells (RBC), at days 16–20 after 5-FU treatment in the peripheral blood of WT mice (Fig. 5A–C). However, we found no significant differences in blood cell recovery kinetics and cell numbers between *Gpr56*-deficient mice and WT littermates. We next sought to determine the involvement of GPR56 signaling in HSC cell cycle regulation during myeloablative stress, as it has been reported that repetitive 5-FU treatment brings HSCs into continuous proliferation and ultimately leads to their exhaustion (25). We treated mice with 5-FU (150mg/kg, i.p.) once per week for a total of 3 weeks, and monitored the survival of mice daily; however, the median survival rates of *Gpr56*-deficient mice were not significantly different from WT littermate controls (13 days vs. 16 days for *Gpr56*-deficient mice and WT mice, respectively; $p=0.106$). (Fig. 5D). These data indicate that *Gpr56*-deficiency does not significantly affect hematopoietic regeneration during hematopoietic recovery from myeloablative stress.

Bone marrow HSPC retention and release are fine-tuned by the orchestrated action of molecular signals generated by cell-intrinsic and extrinsic cues within the BM microenvironment (36, 37). GPR56 has been implicated in the regulation of migration and adhesion of neuronal progenitor cells and various malignant cells via $G\alpha_{12/13}$ and Rho

GTPase signaling pathways (17, 20, 23). We therefore examined whether GPR56 might also be involved in the regulation of HSPC migration. To this end, we performed *in vitro* transwell migration assays to assess the ability of *Gpr56*-deficient HSPCs to migrate in response to a gradient of SDF-1 α (Fig. 6A), a ligand for CXCR4 and a well-described chemoattractant of HSPCs (34, 36). Both WT and *Gpr56*-deficient HSPCs migrated well in response to SDF-1 α , suggesting that *Gpr56*-deficiency on HSPCs does not impair their migratory capacity.

To directly assess the ability of HSPCs to interact with their niche *in vivo*, we next performed an *in vivo* lodgement assay in which an equal number of FACS-purified Lin⁻Kit⁺ cells (enriched for HSPCs) from WT or *Gpr56*-deficient mice BM were fluorescently labeled and transplanted intravenously into non-irradiated WT littermates (38). Sixteen-hours post-transplantation, we assessed the frequency of cells within the BM and spleen (Fig. 6B–D). Labeled cells from *Gpr56*-deficient mice were lodged in the BM ($p=0.74$) and spleen ($p=0.17$) of recipient animals with similar frequency to their WT counterparts. We also analyzed HSPC frequencies in the peripheral blood (PB) and spleen in the steady-state using colony-forming assays and FACS. Both WT and *Gpr56*-deficient mice displayed similar HSPC content in PB and spleen (Fig. 6E–I), suggesting that GPR56 does not regulate bone marrow HSPC retention or trafficking under physiological conditions. Finally, to test the effect of *Gpr56*-deficiency on pharmacologically-induced HSPC mobilization, we treated mice with G-CSF for five days, a commonly used regimen in clinical settings to induce HSPC mobilization for transplantation therapies (28, 34). Again, we saw no differences in circulating HSPC frequencies between G-CSF-treated WT and *Gpr56*-deficient mice (Fig. 6E–I). Collectively, these results suggest that reduction of *Gpr56* does not affect BM HSPC retention or release in the steady-state or in response to G-CSF-induced mobilization.

Discussion

In this study, we explored the expression pattern and functional significance of GPR56 in the regulation of hematopoietic stem and progenitor maintenance and function during steady-state and stress-induced hematopoiesis. We found that *Gpr56* is predominantly expressed in primitive HSPCs during embryonic definitive and adult hematopoiesis and is regulated in adult BM by core HSC transcription factors. Yet, despite its predominant expression in HSCs, high level *Gpr56* expression appears largely dispensable for HSC maintenance in the bone marrow of mice. While we were undertaking this study, Saito et al. (2013), reported that GPR56 signaling maintains HSC quiescence and retention in BM niches via regulation of apoptosis, cell cycle, adhesion, and migration through Rho-GTPase signaling, and in a Evi1-regulated manner (21). However, in our studies, we were unable to identify any differences in HSPC maintenance or differentiation capacity associated with the reduction of GPR56. Although the *Gpr56*^{-/-} mice studied by Saito et al. (2013), and the *Gpr56*-deficient mice used in this study were generated by and obtained from the same source as that used in other studies of GPR56 function (21–24), all of the hematopoietic subsets we investigated, including phenotypic HSPCs and mature cell lineages in bone marrow, spleen, and blood were intact in the *Gpr56*-deficient mice, at least under the conditions tested here. There were, however, subtle phenotypes observed in our *Gpr56*-

deficient mice, including an enlarged thymus, increased frequency of early thymic precursors and CD4⁺ T cells, and lower percentages of CD4⁺ and CD8⁺ T cells among lymphocytes in the spleen suggesting a possible role for GPR56 in the regulation of mature T lymphopoiesis in the thymus. Increased ETP and DN2 frequency despite normal proliferation and survival suggests that in the steady state GPR56 signaling may negatively regulate the entry of progenitors into the thymus. Similar observations were reported for mice deficient for the transcription factor Egr1 (33), although further studies will be required to unravel the cellular and molecular mechanisms through which GPR56 regulates thymus size.

Gpr56-deficient HSPCs displayed proliferation and apoptotic rates similar to that of WT HSPCs *in vivo*. Moreover, in contrast to previous studies (21), *Gpr56*-deficient HSPCs were able to regenerate the hematopoietic system normally in irradiated recipient mice in primary competitive BM transplantation settings. *Gpr56*-deficient HSPCs also displayed a normal pattern of hematopoietic recovery from myelosuppression after treatment with 5-FU *in vivo*, indicating that high levels of *Gpr56* expression are not required for the repopulating activity of HSCs *in vivo*, although the mild impairment of reconstituting activity seen upon serial transplant of *Gpr56*-deficient HSPCs suggests that sustained GPR56 activity may be important for maintaining hematopoietic function during prolonged hematopoietic stress. Our observations that HSPC numbers and functions remain intact in *Gpr56*-deficient mice despite disruption of both *Gpr56* alleles and substantial reduction of GPR56 protein is consistent with a recent report focused on stem cell function in skeletal muscle, which likewise found no significant muscle phenotypes in *Gpr56*-deficient animals or patients (24).

G-protein coupled receptors are highly conserved across species and show structural homology with the other members of this family, and their mechanisms of action can be context-dependent and tissue specific (15, 24, 39). GPR56 signaling has been implicated in the regulation of neuronal progenitor cell adhesion and migration in the brain; however, we failed to detect such functions for GPR56 in HSPCs in the BM microenvironment, illuminating the tissue-specific, and context-dependent regulation of GPR56 signaling. The underlying basis for the distinct functions of GPR56 in the brain versus other tissue remains unclear. It is possible that closely related GPCR proteins or other unknown factors can compensate for reduced GPR56 in the adult hematopoietic, but not neural, progenitors. Potentially confounding compensatory signals arising from hematopoietic and non-hematopoietic cells (such as, HSPC niche components) in response to germline disruption of *Gpr56* and could also provide a selection advantage during homeostasis toward maintaining normal HSPC numbers *in vivo*. Finally, given our surprising observation that residual GPR56 protein can be detected using a mouse anti-human GPR56 monoclonal antibody in *Gpr56*-deficient mice, which previously have been reported to lack this protein entirely based on staining with a rabbit anti-human GPR56 antibody that was pre-cleared with mouse brain homogenates from GPR56 knockout mice, we cannot exclude the possibility that the residual protein expression we detect in these mice (Fig. 2B and Supplemental Fig. S2B–E) is sufficient to mediate the crucial functions of GPR56 in HSPCs, though perhaps not in other cell types. Furthermore, humans and mice harbor four splicing variants of *GPR56*,

among which the S4 variant has its starting ATG in exon 4 of the gene (40). The targeting strategy used to generate the *Gpr56*-deficient mice used in this and prior studies (18, 21, 23, 24) was designed to delete exons 2 and 3, and likely fails to delete the S4 variant. Thus, it is possible that the existing *Gpr56* knockout allele is actually a hypomorphic allele and that the generation of new targeting constructs that delete all forms of GPR56 will reveal a role for this protein in physiological processes that can proceed relatively normally with even very low levels of receptor. It is also possible that different levels of residual protein expression or different ratios of *GPR56* splice variants in *Gpr56*^{-/-} mice housed in different animal facilities might ultimately provide an explanation for the different hematopoietic phenotypes observed in *Gpr56*-deficient mice in our studies and those of Saito et al. (21), as a slightly higher level of residual GPR56 protein in our animals might be sufficient for GPR56 to perform its normal physiological functions. Such impacts of housing conditions on animal phenotype have been noted in other studies, which have further implicated differences in microbiome composition as a critical underlying variable (41). Further studies to identify GPR56 regulatory or compensatory signals and/or conditional deletion of *Gpr56* in specific hematopoietic lineages will be very helpful for further dissecting the activities of Gpr56 in physiological and regenerative hematopoiesis. In any event, our data clearly argue that high level Gpr56 expression is largely dispensable for adult hematopoietic stem and progenitor cell maintenance in the BM niche and regenerative functions in mice.

Summary

This work identifies the G-protein coupled receptor GPR56 as a cell surface protein that is expressed predominantly in long-term reconstituting hematopoietic stem and progenitor cells (HSPCs) in the adult bone marrow and regulated by a core set of hematopoietic transcription factors. However, despite enriched expression in HSPCs, reduced expression of GPR56 in gene-targeted *Gpr56*-deficient mice, revealed only subtle alterations in the hematopoietic compartment, with normal HSPC functions in both steady-state and regenerative hematopoiesis. *Gpr56*-deficiency also did not disrupt the physiological or pharmacologically-induced migration of HSPCs. These data suggest that high-level expression of GPR56 is dispensable for adult blood cell formation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank all the members of Wagers laboratory and E. Gussoni and E. Dzierzak for helpful discussions. We also thank A. Wakabayashi, G. Buruzula and J. LaVecchio at Joslin/HSCI Flow Cytometry Core (NIH P30DK036836) for excellent flow cytometry support, funded in part by NIH P30 DK036836. This work was supported in part by grants from the National Institutes of Health (NIH, OD004345 and HL088582 to AJW and DK67536 and DK103215 to RNK), from the National Health and Medical Research Council of Australia to JEP, and from Leukaemia and Lymphoma Research (LLR) grant 10015 to KO. Content is solely the responsibility of the authors and does not necessarily reflect the official views of the NIH or other funding agencies. The mouse strain used for this research project, B6N.129S5-*Gpr56*^{tm1Lex}/Mmcd, identification number 032342-UCD, was obtained from the Mutant Mouse Regional Resource Center, a NCRRI-NIH funded strain repository, and was donated to the MMRRRC by Genentech, Inc.

Abbreviations

BMT	Bone Marrow Transplantation
BFFP	Bilateral Frontoparietal Polymicrogyria
G-CSF	Granulocyte Colony Stimulating Factor
GPR56	G-Protein Coupled Receptor 56
GPCRs	G-Protein Coupled Receptors
HSCs	Hematopoietic Stem Cells
HSPCs	Hematopoietic Stem and Progenitor Cells
5-FU	5-Fluoro Uracil

References

- Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. *Cell*. 2008; 132(4): 631–44. [PubMed: 18295580]
- Wilson NK, Foster SD, Wang X, Knezevic K, Schutte J, Kaimakis P, Chilarska PM, Kinston S, Ouwehand WH, Dzierzak E, Pimanda JE, de Bruijn MF, Gottgens B. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. *Cell stem cell*. 2010; 7(4):532–44. Epub 2010/10/05. 10.1016/j.stem.2010.07.016 [PubMed: 20887958]
- Ling KW, Ottersbach K, van Hamburg JP, Oziemlak A, Tsai FY, Orkin SH, Ploemacher R, Hendriks RW, Dzierzak E. GATA-2 plays two functionally distinct roles during the ontogeny of hematopoietic stem cells. *J Exp Med*. 2004; 200(7):871–82. [PubMed: 15466621]
- Beck D, Thoms JA, Perera D, Schutte J, Unnikrishnan A, Knezevic K, Kinston SJ, Wilson NK, O'Brien TA, Gottgens B, Wong JW, Pimanda JE. Genome-wide analysis of transcriptional regulators in human HSPCs reveals a densely interconnected network of coding and noncoding genes. *Blood*. 2013; 122(14):e12–22. Epub 2013/08/27. 10.1182/blood-2013-03-490425 [PubMed: 23974199]
- Wang LD, Wagers AJ. Dynamic niches in the origination and differentiation of haematopoietic stem cells. *Nat Rev Mol Cell Biol*. 2011; 12(10):643–55. Epub 2011/09/03. nrm3184 [pii]. 10.1038/nrm3184 [PubMed: 21886187]
- Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. *J Exp Med*. 2011; 208(3):421–8. Epub 2011/03/16. jem.20110132 [pii]. 10.1084/jem.20110132 [PubMed: 21402747]
- Levesque JP, Winkler IG. Hierarchy of immature hematopoietic cells related to blood flow and niche. *Current opinion in hematology*. 2011; 18(4):220–5. Epub 2011/04/27. 10.1097/MOH.0b013e3283475fe7 [PubMed: 21519242]
- Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. “Stemness”: transcriptional profiling of embryonic and adult stem cells. *Science*. 2002; 298(5593):597–600. [PubMed: 12228720]
- Gazit R, Garrison BS, Rao TN, Shay T, Costello J, Ericson J, Kim F, Collins JJ, Regev A, Wagers AJ, Rossi DJ. Transcriptome analysis identifies regulators of hematopoietic stem and progenitor cells. *Stem Cell Reports*. 2013; 1(3):266–80. Epub 2013/12/10. 10.1016/j.stemcr.2013.07.004 [PubMed: 24319662]
- Forsberg EC, Passegue E, Prohaska SS, Wagers AJ, Koeva M, Stuart JM, Weissman IL. Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. *PLoS One*. 2010; 5(1):e8785. [PubMed: 20098702]

11. Venezia TA, Merchant AA, Ramos CA, Whitehouse NL, Young AS, Shaw CA, Goodell MA. Molecular signatures of proliferation and quiescence in hematopoietic stem cells. *PLoS Biol.* 2004; 2(10):e301. [PubMed: 15459755]
12. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. *Science.* 2002; 298(5593):601–4. [PubMed: 12228721]
13. Riddell J, Gazit R, Garrison BS, Guo G, Saadatpour A, Mandal PK, Ebina W, Volchkov P, Yuan GC, Orkin SH, Rossi DJ. Reprogramming committed murine blood cells to induced hematopoietic stem cells with defined factors. *Cell.* 2014; 157(3):549–64. Epub 2014/04/29. 10.1016/j.cell.2014.04.006 [PubMed: 24766805]
14. Laird DJ, von Andrian UH, Wagers AJ. Stem cell trafficking in tissue development, growth, and disease. *Cell.* 2008; 132(4):612–30. [PubMed: 18295579]
15. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. Molecular signatures of G-protein-coupled receptors. *Nature.* 2013; 494(7436):185–94. Epub 2013/02/15. 10.1038/nature11896 [PubMed: 23407534]
16. Langenhan T, Aust G, Hamann J. Sticky signaling--adhesion class G protein-coupled receptors take the stage. *Science signaling.* 2013; 6(276):re3. Epub 2013/05/23. 10.1126/scisignal.2003825 [PubMed: 23695165]
17. Iguchi T, Sakata K, Yoshizaki K, Tago K, Mizuno N, Itoh H. Orphan G protein-coupled receptor GPR56 regulates neural progenitor cell migration via a G alpha 12/13 and Rho pathway. *The Journal of biological chemistry.* 2008; 283(21):14469–78. Epub 2008/04/02. 10.1074/jbc.M708919200 [PubMed: 18378689]
18. Luo R, Jeong SJ, Jin Z, Strokes N, Li S, Piao X. G protein-coupled receptor 56 and collagen III, a receptor-ligand pair, regulates cortical development and lamination. *Proceedings of the National Academy of Sciences of the United States of America.* 2011; 108(31):12925–30. Epub 2011/07/20. 10.1073/pnas.1104821108 [PubMed: 21768377]
19. Piao X, Hill RS, Bodell A, Chang BS, Basel-Vanagaite L, Straussberg R, Dobyns WB, Qasrawi B, Winter RM, Innes AM, Voit T, Ross ME, Michaud JL, Descarie JC, Barkovich AJ, Walsh CA. G protein-coupled receptor-dependent development of human frontal cortex. *Science.* 2004; 303(5666):2033–6. Epub 2004/03/27. 10.1126/science.1092780 [PubMed: 15044805]
20. Shashidhar S, Lorente G, Nagavarapu U, Nelson A, Kuo J, Cummins J, Nikolich K, Urfer R, Foehr ED. GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. *Oncogene.* 2005; 24(10):1673–82. Epub 2005/01/28. 10.1038/sj.onc.1208395 [PubMed: 15674329]
21. Saito Y, Kaneda K, Suekane A, Ichihara E, Nakahata S, Yamakawa N, Nagai K, Mizuno N, Kogawa K, Miura I, Itoh H, Morishita K. Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVII-regulated GPR56. *Leukemia.* 2013; 27(8):1637–49. Epub 2013/03/13. 10.1038/leu.2013.75 [PubMed: 23478665]
22. Li S, Jin Z, Koirala S, Bu L, Xu L, Hynes RO, Walsh CA, Corfas G, Piao X. GPR56 regulates pial basement membrane integrity and cortical lamination. *The Journal of neuroscience : the official journal of the Society for Neuroscience.* 2008; 28(22):5817–26. Epub 2008/05/30. 10.1523/JNEUROSCI.0853-08.2008 [PubMed: 18509043]
23. Koirala S, Jin Z, Piao X, Corfas G. GPR56-regulated granule cell adhesion is essential for rostral cerebellar development. *The Journal of neuroscience : the official journal of the Society for Neuroscience.* 2009; 29(23):7439–49. Epub 2009/06/12. 10.1523/JNEUROSCI.1182-09.2009 [PubMed: 19515912]
24. Wu MP, Doyle JR, Barry B, Beauvais A, Rozkalne A, Piao X, Lawlor MW, Kopin AS, Walsh CA, Gussoni E. G-protein coupled receptor 56 promotes myoblast fusion through serum response factor- and nuclear factor of activated T-cell-mediated signalling but is not essential for muscle development in vivo. *The FEBS journal.* 2013; 280(23):6097–113. Epub 2013/10/10. 10.1111/febs.12529 [PubMed: 24102982]
25. Schepers K, Hsiao EC, Garg T, Scott MJ, Passegue E. Activated Gs signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice. *Blood.* 2012; 120(17):3425–35. Epub 2012/08/04. 10.1182/blood-2011-11-395418 [PubMed: 22859604]
26. Fitch SR, Kimber GM, Wilson NK, Parker A, Mirshekar-Syahkal B, Gottgens B, Medvinsky A, Dzierzak E, Ottersbach K. Signaling from the sympathetic nervous system regulates hematopoietic

- stem cell emergence during embryogenesis. *Cell stem cell*. 2012; 11(4):554–66. Epub 2012/10/09. 10.1016/j.stem.2012.07.002 [PubMed: 23040481]
27. Jeong SJ, Luo R, Li S, Strokes N, Piao X. Characterization of G protein-coupled receptor 56 protein expression in the mouse developing neocortex. *The Journal of comparative neurology*. 2012; 520(13):2930–40. Epub 2012/02/22. 10.1002/cne.23076 [PubMed: 22351047]
 28. Neben S, Marcus K, Mauch P. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. *Blood*. 1993; 81(7):1960–7. [PubMed: 7681707]
 29. Chambers SM, Boles NC, Lin KY, Tierney MP, Bowman TV, Bradfute SB, Chen AJ, Merchant AA, Sirin O, Weksberg DC, Merchant MG, Fisk CJ, Shaw CA, Goodell MA. Hematopoietic fingerprints: an expression database of stem cells and their progeny. *Cell stem cell*. 2007; 1(5): 578–91. Epub 2008/03/29. 10.1016/j.stem.2007.10.003 [PubMed: 18371395]
 30. Solaimani Kartalaei P, Yamada-Inagawa T, Vink CS, de Pater E, van der Linden R, Marks-Bluth J, van der Sloot A, van den Hout M, Yokomizo T, van Schaick-Solerno ML, Delwel R, Pimanda JE, van IWF, Dzierzak E. Whole-transcriptome analysis of endothelial to hematopoietic stem cell transition reveals a requirement for Gpr56 in HSC generation. *The Journal of experimental medicine*. 2015; 212(1):93–106. 10.1084/jem.20140767 [PubMed: 25547674]
 31. Bagger FO, Rapin N, Theilgaard-Monch K, Kaczkowski B, Jendholm J, Winther O, Porse B. HemaExplorer: a Web server for easy and fast visualization of gene expression in normal and malignant hematopoiesis. *Blood*. 2012; 119(26):6394–5. Epub 2012/06/30. 10.1182/blood-2012-05-427310 [PubMed: 22745298]
 32. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. *Cell*. 2005; 121(7):1109–21. [PubMed: 15989959]
 33. Schnell FJ, Zoller AL, Patel SR, Williams IR, Kersh GJ. Early growth response gene 1 provides negative feedback to inhibit entry of progenitor cells into the thymus. *J Immunol*. 2006; 176(8): 4740–7. Epub 2006/04/06. [PubMed: 16585567]
 34. Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. *J Exp Med*. 2002; 195(9):1145–54. [PubMed: 11994419]
 35. Passegue E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. *J Exp Med*. 2005; 202(11):1599–611. [PubMed: 16330818]
 36. Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. *Experimental hematology*. 2006; 34(8):967–75. Epub 2006/07/26. 10.1016/j.exphem.2006.04.002 [PubMed: 16863903]
 37. Greenbaum AM, Link DC. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. *Leukemia*. 2011; 25(2):211–7. Epub 2010/11/17. 10.1038/leu.2010.248 [PubMed: 21079612]
 38. Luo B, Lam BS, Lee SH, Wey S, Zhou H, Wang M, Chen SY, Adams GB, Lee AS. The endoplasmic reticulum chaperone protein GRP94 is required for maintaining hematopoietic stem cell interactions with the adult bone marrow niche. *PLoS One*. 2011; 6(5):e20364. Epub 2011/06/08. PONE-D-11-02406 [pii]. 10.1371/journal.pone.0020364 [PubMed: 21647226]
 39. Kinzer-Ursem TL, Linderman JJ. Both ligand- and cell-specific parameters control ligand agonism in a kinetic model of g protein-coupled receptor signaling. *PLoS computational biology*. 2007; 3(1):e6. Epub 2007/01/16. 10.1371/journal.pcbi.0030006 [PubMed: 17222056]
 40. Kim YJ, Huh JW, Kim DS, Bae MI, Lee JR, Ha HS, Ahn K, Kim TO, Song GA, Kim HS. Molecular characterization of the DYX1C1 gene and its application as a cancer biomarker. *Journal of cancer research and clinical oncology*. 2009; 135(2):265–70. Epub 2008/07/12. 10.1007/s00432-008-0445-8 [PubMed: 18618141]
 41. Kriegel MA, Sefik E, Hill JA, Wu HJ, Benoist C, Mathis D. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108(28):11548–53. 10.1073/pnas.1108924108 [PubMed: 21709219]

Highlights

- Gpr56 is highly expressed in HSPCs during definitive hematopoiesis in the mouse embryo and is a heptad target.
- Gpr56 is expressed predominantly in primitive HSPCs in the adult BM, but is dispensable for steady-state and stress hematopoiesis
- Gpr56-deficient donor HSCs efficiently reconstitute hematopoiesis after bone marrow transplantation in primary recipients, but show reduced reconstitution ability in secondary recipients.
- Gpr56-deficiency does not affect physiological or pharmacologically induced migration of HSPCs.




Figure 1. *Gpr56* is expressed in HSCs during definitive hematopoiesis in the mouse embryo and is a Heptad target

(A). Venn diagram showing the overlap between two data sets, one from ChIP-Seq data in HPC7 progenitor cells containing genes with combinatorial binding regions bound by seven key HSC transcription factors (*Scf*, *Gata2*, *Runx1*, *Erg*, *Fli1*, *Lyl1* and *Lmo2*; Heptad targets) (2) and the other comparing gene expression in quiescent *versus* proliferating HSCs (Q group) (11). The overlap (n=81) between these two data sets was further filtered for cell surface receptors, identifying 8 receptors (Supplemental Table S1). (B). In situ hybridization for *Gpr56* showing transcript expression in blood clusters and adjacent endothelium in E11 AGM and in E11 FL blood cells. (C). Quantitative PCR for *Gpr56* and its ligand *Col3a* in E11 AGM endothelial cells (EC; CD34⁺CD45⁻), E11AGM mesenchymal cells (MC; CD34⁻CD45⁻cKit⁻), E11 AGM hematopoietic stem cells (HSC; CD34⁺CD45⁺cKit⁺CD41^{int}); E11, E12 FL HSC; CD34⁺ckit⁺ and E14 FL HSC; Lin⁻CD45⁺ CD48⁻ CD150⁺ EPCR⁺.




Figure 2. *Gpr56* is highly expressed in adult HSCs, but dispensable for maintaining HSPC numbers in the steady-state

(A). *Gpr56* expression was quantified by qRT-PCR analysis in the indicated FACS-purified HSPCs of WT C57BL/6 mice. Expression values in each subset were normalized to an internal control (*β-actin* gene). Data are plotted as fold-expression relative to *Gpr56* expression in Lineage negative (*Lin*⁻) cells, whose expression was arbitrarily set to one. Data represent mean ± SD, n=4 independent samples from two independent experiments. (B). Expression of GPR56 on the cell surface of the indicated BM HSPC subsets from WT and *Gpr56*-deficient mice was determined by FACS using anti-GPR56 antibody (clone: CG4). (C). Total BM cell numbers of 8–14 week old *Gpr56*-deficient mice and WT littermates. Cell counts determined from two tibias and two femurs from each mouse (n=8 mice per group). (D). Representative FACS plots showing the percentages of HSPC subsets (as indicated) in the BM of WT and *Gpr56*-deficient mice. *Lin*⁻*Sca1*⁺*ckit*⁺ (LSK) cells (left plots) were further fractionated based on CD34 and CD135 expression levels into LT-HSCs (LSKCD34⁻CD135⁻), ST-HSCs (LSKCD34⁺CD135⁻), and MPPs (LSKCD34⁺CD135⁺) (right plots). (E). Bar graph indicating the frequency of indicated subsets in the whole BM of WT and *Gpr56*-deficient mice. Data represent mean ± SEM, n=10 independent samples from 3 independent experiments. (F). Representative FACS plots showing the percentages of HSC-SLAM cells (LSKCD48⁻CD150⁺), and graph summarizing HSC-SLAM frequency in whole BM of WT and *Gpr56*-deficient mice. (G). Detection of myeloid progenitors in the BM by FACS. *Lin*⁻*Sca1*⁻*c-Kit*⁺ myeloid progenitors (MPs, left FACS plots) were subdivided according to CD34 and FcγRII/III expression (right FACS plots), the common myeloid progenitors (CMP, *Lin*⁻*Sca1*⁻*c-Kit*⁺CD34⁺FcγRII/III^{med}), granulocyte monocyte

progenitors (GMPs, Lin⁻Sca-1⁻c-Kit⁺CD34⁺FcγRII/III⁺), and megakaryocyte erythrocyte progenitors (MEPs, Lin⁻Sca-1⁻c-Kit⁺CD34⁻FcγRII/III^{low}). (H). Frequencies of the indicated subsets in whole BM of WT and *Gpr56*-deficient mice. Data represent mean ± SEM, n=5 independent samples from two independent experiments. (I). FACS plots and graph represent the frequency of common lymphoid progenitors (CLPs, Lin⁻CD127⁺CD135⁺) in the whole BM of WT and *Gpr56*-deficient mice. Data are mean ± SEM, n=7–10 mice from 3 independent experiments.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3. Enlarged thymus and increased frequency of early thymic precursors in *Gpr56*-deficient mice

(A). Representative photographs of thymuses from 10-week-old WT and *Gpr56*-deficient mice. (B). Increased thymic cellularity in *Gpr56*-deficient mice. Graph shows the absolute number of thymocytes from the indicated age group of WT or *Gpr56*-deficient mice (mean ± SEM, n=9–12 mice). (C). Hematoxylin and eosin (H&E) staining of thymus from 12-week old WT and *Gpr56*-deficient mice (representative of n=4 per genotype) (m: medulla; c: cortex). (D). FACS contour plots display the distribution and percentages of immature thymocyte subsets within the Lin⁻ fraction of thymocytes from 10-week-old WT and *Gpr56*-deficient mice. (E–F). Graphs show the frequencies (E) and absolute number of thymocytes (F) of indicated immature thymocyte subsets in the thymus (n=12 mice per genotype, mean ± SEM). (G). Thymocytes from 10-week-old WT and *Gpr56*-deficient mice were surface stained for CD4 and CD8 to assess thymocyte differentiation. FACS plots show the distribution of DN (CD4⁻/CD8⁻), DP (CD4⁺/CD8⁺), CD4⁺ and CD8⁺ cells. Graphs show the percentages of indicated subsets in the thymus (n=11 mice). (H). Mice were treated by i.p. Injection of 1mg of BrdU and sacrificed 5 hours later. The data show percentage of cells with BrdU-incorporation in the indicated thymic subsets (n=5, means ± SEM). (I). Apoptosis rates in the thymocytes from 8-week-old WT and *Gpr56*-deficient

mice were determined by Annexin V/7-AAD staining. Percentages of apoptotic cells are summarized in the graph (n=5, means \pm SEM). * p <0.05, ** p <0.01, and *n.s.* (not significant).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. *Gpr56* deficiency does not impair HSC engraftment and multi-lineage repopulating activity in vivo
 (A). Representative FACS plots show the distribution of cell cycle stages of BM HSPC subsets from WT or *Gpr56*-deficient mice. BM cells were first surface stained to define the HSPC subsets and further stained intracellularly for Ki-67 and Hoechst 33342. (B). The percentages of cells in each stage of cell cycle: G0 (Ki-67^{lo} Hoechst⁻), G1 (Ki-67⁺ Hoechst⁻), and S/G2/M (Ki-67⁺ Hoechst⁺), are summarized in the graph. (n=5 mice per genotype, mean ± SEM). (C). Apoptosis rates among BM LSK cells from WT or *Gpr56*-deficient mice as determined by Annexin V/7-AAD staining. Representative FACS plots show the percentages of apoptotic cells among LSK cells. The bar graph represents the percentages of early apoptotic cells (Annexin V⁺ 7-AAD⁻) among LSK cells (n=8 mice per genotype, mean ± SEM). (D). Schematic of serial competitive transplantation assay: Total BM cells from CD45.2⁺ WT or *Gpr56*-deficient mice were mixed with equal numbers of congenic (CD45.1⁺) recipient-type BM cells (1:1) and competitively transplanted into lethally irradiated primary (CD45.1⁺) recipient mice. After 20 weeks, total BM from

primary recipients was transplanted into secondary recipients at 1×10^6 cells per secondary recipient. **(E–H)**. Donor chimerism (CD45.2⁺) in primary recipient mice was determined by FACS analysis of peripheral blood. Bar graphs show the percentages of total donor cells (CD45.2⁺) **(E)**; donor B-cells (CD45.2⁺B220⁺) **(F)**; donor myeloid cells (CD45.2⁺CD11b⁺Gr1⁺) **(G)**; and donor-T cells (CD45.1⁺ CD3⁺) **(H)** at the indicated time points (n=7–8 mice, mean \pm SD). **(I–J)**. At 20-weeks after transplantation, recipient BM was analyzed for total donor-derived cells (CD45.2⁺) **(I)** and donor LSK frequency **(J)**. (n=7 mice, mean \pm SD). **(K–M)**. Analysis of secondary BM transplant recipients. Donor chimerism in peripheral blood at 4 and 12 weeks post-transplant **(K)**. Total donor chimerism in BM **(L)**. Percent donor-derived LSK cells in the BM at 12 weeks after secondary transplantation (n=6 mice, mean \pm SD) **(M)**. * $p < 0.05$, ** $p < 0.01$, and *n.s.* (not significant).




Figure 5. Normal hematopoietic recovery and survival of *Gpr56*-deficient mice after myelosuppressive treatment with 5-FU

Eight to ten week-old WT and *Gpr56*-deficient mice were intravenously injected with a single dose of 5-FU (150mg/kg), and the kinetics of hematopoietic recovery was measured in the peripheral blood at the indicated time. Recovery of white blood cells (WBC) (A), platelets (B), and red blood cells (RBC) (C). Data are from 2 independent experiments (n=8–10 mice, plotted as mean ± SD). (D). *Gpr56*-deficient mice exhibit normal sensitivity to repetitive myelosuppressive stress. Mice were injected intraperitoneally with 5-FU weekly for a total of 3 weeks, and survival was monitored daily. Survival data were analyzed using a log-rank nonparametric test (Mantel-Cox test), and shown as Kaplan-Meier survival curves (n=12 animals per genotype over two independent experiments).




Figure 6. *Gpr56* deficiency does not affect the physiological or pharmacologically-induced migration of HSPCs
(A). *In vitro* migration of FACS isolated LSK cells from WT or *Gpr56*-deficient mice was assessed in Transwell migration assays. The percentage of migrated cells after 4 hours was determined for spontaneous migration (no SDF-1 α) or in response to chemotactic signals (toward 100ng/ml of SDF-1 α gradient). Cell migration was quantified by FACS analysis (n=4 mice per experimental group, mean \pm SD). **(B).** Schematic of *in vivo* lodging assay. **(C).** Representative FACS plots showing the percentages of labeled lodged cells (PKH67⁺ cells, green) in the BM and spleen of recipient mice. **(D).** Bar graph summarizes the frequency of lodged cells among the live BM and spleen cells (n=4 animals per group, mean

± SD. **(E)**. Total number of colonies formed from PB cells (1×10^5) from WT or *Gpr56*-deficient mice (n=4–5 per genotype) in methylcellulose based colony-forming unit (CFU) activity assay (mean ± SD. **(F and H)**). FACS contour plots show the percentages of LSK and myeloid progenitor cells (LS⁻K⁺) among the Lin⁻ cells of peripheral blood (**F**), and spleen (**H**) from untreated (top) or G-CSF-treated (bottom) WT or *Gpr56*-deficient animals. Graphs show the frequencies of LSK cells in the peripheral blood (**G**), and spleen (**I**) from untreated and G-CSF treated WT and *Gpr56*-deficient mice. Data are plotted as mean ± SD, from two independent experiments (n=7–8 animals per group).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1Differential blood cell counts on peripheral blood from *Gpr56*^{+/+} and *Gpr56*^{def} littermates

Parameter	<i>Gpr56</i> ^{+/+}	<i>Gpr56</i> ^{def}	<i>p</i> -value
WBCs (K/μL)	9.29 \pm 5.12	6.87 \pm 3.78	0.20
Neutrophils (K/μL)	2.71 \pm 1.91	1.56 \pm 0.75	0.10
Lymphocytes (K/μL)	5.74 \pm 4.09	5.03 \pm 3.04	0.64
Monocytes (K/μL)	0.51 \pm 0.3	0.24 \pm 0.29	0.13
Eosinophils (K/μL)	0.26 \pm 0.19	0.03 \pm 0.03	0.06
Basophils (K/μL)	0.04 \pm 0.07	0.01 \pm 0.01	0.12
RBC (M/μL)	9.42 \pm 1.25	9.03 \pm 2.21	0.58
Hb (g/dL)	12.84 \pm 1.89	12.33 \pm 3.21	0.64
HCT (%)	46.65 \pm 6.21	45.57 \pm 12.05	0.78
MCV (fL)	49.46 \pm 2.89	50.13 \pm 2.58	0.58
PLT (K/μL)	766.58 \pm 200.12	829.42 \pm 206.48	0.43

Values shown are means \pm SEM ($n=12$ mice per group). WBC indicates white blood cell; RBC, red blood cell; Hb, hemoglobin; HCT hematocrit; MCV, mean corpuscular volume; PLT, platelets. No statistically significant differences were detected.